跳至主要内容
临床试验/NCT04584580
NCT04584580Unknown4 期

D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia

Ain Shams University1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2020年8月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
50
试验地点
1
主要终点
mortality

研究概览

简要总结

evaluation of the efficacy and safety of D-dimer adjusted heparin versus therapeutic dose heparin in patients with COVID-19 Pneumonia.

详细描述

The following will be done for enrolled patients:

  1. Data collection: name, age, sex, special habits of medical importance (i.e. smoking, drug abuse), comorbid conditions.
  2. Clinical examination Vital data Local chest examination
  3. Measurement of oxygen saturation using pulse oximeter
  4. Laboratory investigations:

Complete blood count with differential count Liver and kidney functions D-dimer level Coagulation profile 5. Radiology work up ( Chest X-ray-High resolution computed tomography of the chest- computed tomography of the chest with pulmonary angiography as needed) 6. Sepsis-induced coagulopathy score (SIC score) 7. Sequential organ failure score (SOFA score) 8. Patients will receive treatment according to the hospital guidelines for different disease stratification severity

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All adult (>18 years) patients from both sexes with COVID-19 pneumonia with positive nucleic acid test for severe acute respiratory syndrome Coronavirus (SARS-CoV-2) hospitalized either in the ward or intensive care unit

排除标准

  • Patients with absolute contraindication of pharmacological thromboprophylaxis and/ anticoagulation
  • Congenital hemorrhagic disorders
  • Hypersensitivity to heparin
  • Personal history of heparin-induced thrombocytopenia
  • Active major bleeding or conditions predisposing to major bleeding. Major bleeding is defined as fulfilling any one of these three criteria: a) occurs in a critical area or organ (e.g.intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, intra-uterine or intramuscular with compartment syndrome), b) causes a fall in haemoglobin level (Hb) of ≥2g/dL in a 24h period, or c) leads to transfusion of 2 or more units of whole blood or red blood cells (13).
  • Suspected or confirmed bacterial endocarditis
  • Ongoing or planned therapeutic anticoagulation for any other indication
  • Platelet count <50,000/μL within the past 24 hours or Hb level <8g/dL
  • Prothrombin time (PT) ≥2 seconds above the upper limit of age-appropriate local reference range within the past 24 hours
  • Activated partial thromboplastin time (aPTT) ≥4 seconds above the upper limit of age-appropriate local reference range within the past 24 hours
  • Fibrinogen <2.0 g/L
  • Severe renal impairment (CrCl<30 mL/min) or acute kidney injury
  • Use of dual antiplatelet therapy
  • Pregnancy
  • Unwillingness to consent

研究组 & 干预措施

Therapeutic dose low-molecular-weight heparin (LMWH)

Active Comparator

Therapeutic dose low-molecular-weight heparin from admission until the end of hospital stay Enoxaparin 1 mg/kg subcutaneous every 12 hours

干预措施: low-molecular-weight heparin (Drug)

D-dimer levels and weight adjusted low-molecular-weight heparin (LMWH)therapy

Experimental

from admission until the end of hospital stay. Patients will be stratified according to their body weight and D-dimer level and receive LMWH

D-Dimer level Body Weight LMWH dose

<1 mg/dl <100kg Enoxaparin 40mg OD 100-150kg Enoxaparin 40mg BD >150kg Enoxaparin 60mg BD

1-3 mg/ dl <100kg Enoxaparin 40mg BD 100-150kg Enoxaparin 80mg BD >150kg Enoxaparin 120mg BD

>3 mg/ dl Enoxaparin 80mg BD

干预措施: low-molecular-weight heparin (Drug)

结局指标

主要结局

mortality

时间窗: Until patient is discharged or up to 4 weeks whichever comes first

All cause mortality

occurrence of venous and/or arterial thrombosis

时间窗: Until patient is discharged or up to 4 weeks whichever comes first

clinical signs supported by radiological evidence of arterial thrombosis or venous thromboembolism (e.g. venous or arterial duplex and CT scan of the chest with pulmonary angiography)

次要结局

  • occurrence of Sepsis-induced coagulopathy(Until patient is discharged or up to 4 weeks whichever comes first)
  • Occurrence of adult respiratory distress syndrome (ARDS)(Until patient is discharged or up to 4 weeks whichever comes first)
  • Occurrence of sepsis(Until patient is discharged or up to 4 weeks whichever comes first)
  • ICU admission and need for mechanical ventilation(Until patient is discharged or up to 4 weeks whichever comes first)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ashraf M Madkour

Professor

Ain Shams University

研究点 (1)

Loading locations...

相似试验